USA flag logo/image

An Official Website of the United States Government

Modulation of the Innate Immune System by Fisetin for the Treatment of AD

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / STTR
Agency Tracking Number:
R41AI104034
Solicitation Year:
2013
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-124
Small Business Information
VIROGENICS, INC.
PO BOX 2702 DEL MAR, CA 92014-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Modulation of the Innate Immune System by Fisetin for the Treatment of AD
Agency: HHS
Contract: 1R41AI104034-01A1
Award Amount: $599,936.00
 

Abstract:

DESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most prevalent age-associated disease and growing evidence suggeststhat aspects of the innate immune system play a major role its progression. Based on this evidence, we propose a new approach to the treatment of AD by targeting key properties of the innate immune system involved in the progression of the disease. Microglia (or brain macrophages) are the resident immune cells of the brain. Not only are they implicated in the pathogenesis of a variety of neurological disorders including AD but they also play important, protective roles in the CNS. Thus, modulating the response of microglia following activation to favor their neuroprotective over their neurotoxic properties may be the key to harnessing the immune system to treat AD. Our studies have led to the identification of a molecule that controls microglial propertiesin ways that are beneficial for modulating AD progression. This is the flavonoid fisetin which our in vitro and animal studies have demonstrated inhibits TNF production in activated macrophages and microglia. Fisetin promotes the adoption of the M2 anti-inflammatory phenotype by microglia as manifested by an increase in the expression of CD45, a cell surface protein tyrosine phosphatase expressed exclusively by cells of hematopoietic lineages and by inhibition of iNOS induction. CD45 has been implicated inthe inhibition of classical M1 microglial activation while driving the anti-inflammatory M2 microglial phenotype. Fisetin, a rare natural flavonoid, was initially identified in the Maher laboratory as a orally active, novel neuroprotective and cognition-enhancing molecule. Fisetin protects nerve cells from multiple toxic insults and is therapeutically active in rigorous rodent models for memory, rabbit and mouse models for ischemic stroke, mouse and fly models of Huntington's disease and in transgenic AD mice. A series of much more potent fisetin derivatives, many of which maintain in vitro anti-inflammatory activity, has recently been synthesized by SAR-driven iterative chemistry. From the 150 derivatives synthesized, we selected the best seven derivativesthat maintain the biological activities of fisetin, including its anti-inflammatory actvity. Preliminary assays to assess their pharmacological properties indicate that these derivatives have the potential to be good CNS drugs. In addition, the derivativesdo not suffer from the intellectual property challenges of the natural product fisetin and are covered under several issued and/or pending patents held by the Salk Institute. We propose to advance fisetin derivatives as modulators of innate immune function and clinical candidates for the treatment of AD. Specifically, we plan to (1) further characterize the induction of the M2 microglial phenotype by fisetin and fisetin derivatives in vitro; (2) identify which of the pre-selected fisetin derivatves inducethe M2 phenotype in vivo and then determine which have pharmacokinetic properties most consistent with good CNS drugs and (3) test the best two fisetin derivatives in AD transgenic mice for effects on behavior and pathology. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Currently there are no drugs that can prevent, slow or stop the progression of Alzheimer's disease. We propose to develop a novel group of compounds based on a small molecule natural product to harness the good aspects of the brain's immune system in order to prevent the loss of brain function in Alzheimer's disease. If successful, this approach could prove beneficial for the treatment not only of Alzheimer's disease but also a number of other age-related neurological disorders.

Principal Investigator:

Pamela A. Maher
858-453-4100
pmaher@salk.edu

Business Contact:

William C. Raschke
858-450-2561
braschke@virogenicsinc.com
Small Business Information at Submission:

VIROGENICS, INC.
PO BOX 2702 DEL MAR, CA 92014-

EIN/Tax ID: 142157802
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
SALK INSTITUTE FOR BIOLOGICAL STUDIES
10010 N TORREY PINES RD
LA JOLLA, CA 92037-1002
Contact: